7th Inflammation in Drug Discovery & Development, San Diego, CA, USA
Event Feb 20
Efforts to discover and develop safer and more effective therapies for rheumatoid arthritis (RA) are based on our improved understanding of the many inflammatory mediators that contribute to the pathogenesis of the disease. This has resulted in the successful approvals of the TNF and IL-1 blockers which are protein drugs (biologics). Several small molecules to modifying these inflammatory mediators and additional cytokines and chemokines are also under intensive investigation. Selective targeting of B cells, T cells as well as novel gene products are also under preclinical and clinical evaluation.